Twice-Yearly Injection Shows Promise for Controlling Resistant High Blood Pressure

Tue, 14 Apr 2026 17:31:00 +0200

A recent global clinical trial led by Queen Mary University of London has revealed that a new injectable drug, zilebesiran, may significantly improve blood pressure management. The study, published in JAMA, involved 663 adults whose blood pressure was not well controlled with standard medications. Patients who received a six-monthly injection of zilebesiran in addition to their usual therapy experienced greater reductions in blood pressure compared to those on standard treatment alone. Zilebesiran works by using RNA interference to block the production of angiotensinogen, a liver protein that regulates blood pressure, allowing blood vessels to relax. Experts, including Dr. Manish Saxena, highlight the potential impact of this long-lasting treatment, which could simplify hypertension management for millions. Ongoing studies, including KARDIA-3 and a planned global outcomes study, aim to explore its effects in patients with cardiovascular disease and assess its potential to reduce major